EPO
Recombinant human erythropoietin (rhEPO). Stimulates red blood cell production, WADA-banned in endurance sports.
WHAT IS EPO?
Detailed overview
Recombinant human erythropoietin (rhEPO, Epoetin alfa/beta, Procrit, Eprex, Aranesp) is the biologically identical form of natural kidney-produced EPO. FDA-approved for chronic kidney disease, chemo-induced anemia, and prematurity anemia. In endurance sports (cycling, distance athletics) off-label use raises hematocrit, with anecdotal +8-10% VO2max (Lundby 2011) but blinded placebo-controlled RCTs showing a realistic +1-3% performance gain (Heuberger 2013). WADA-banned; erythropoietic stimulation carries serious thrombotic + cardiovascular risk (blood viscosity rise). **HIF-α stabilization analogy**: endogenous renal EPO is activated by hypoxia-induced HIF-α (Semenza Nobel 2019); rhEPO mimics this signal as an exogenous receptor agonist. **Historical context**: the Tour de France 1990-2000 "EPO era" (Festina scandal 1998), Lance Armstrong USPS protocol documented (USADA 2012). **Detection breakthrough**: Lasne & de Ceaurriz 2000 Nature (PMID 10864312) IEF testing. **Hematocrit ramp dynamics**: 7-10 days post-SC reticulocyte peak, 21-28 day hematocrit peak – hence the spread of micro-dose protocols (20-30 IU/kg every other day) for sub-detection-window boosting.
Mechanism
EPO receptor agonist, erythropoiesis-stimulating
Half-life
5-13 h (subcutaneous)
Onset
7-14 days (reticulocyte rise)
Legal status
USA: FDA Rx (Procrit). EU: Rx. WADA: banned.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Rise in hematocrit and blood viscosity with thrombotic events (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction), especially above 50-55% hematocrit or with dehydration – FDA black-box warning.
- Hypertension and blood-pressure spikes; in severe cases hypertensive encephalopathy and seizures.
- Pure red cell aplasia (PRCA) from neutralizing anti-EPO antibodies – rare but serious, causing transfusion-dependent anemia, mainly with subcutaneous dosing.
- Functional iron deficiency: accelerated erythropoiesis depletes iron stores, and without iron supplementation the effect fails and microcytic anemia can develop.
- Flu-like symptoms after injection: joint, muscle and bone pain, chills, headache (especially with intravenous bolus).
- Injection-site reactions: pain, redness, itching and swelling at the subcutaneous injection site.
- In cancer patients, increased tumor progression and mortality with shortened survival (FDA black-box; ESAs can stimulate tumor growth).
- As a doping agent, extreme hematocrit elevation can cause blood "sludging" during the low heart rate of sleep – the phenomenon linked to sudden deaths in the 1990-2000 "EPO era".
Contraindications · 7
- Uncontrolled or severe hypertension – EPO further raises blood pressure and can provoke a hypertensive crisis.
- Thrombophilia or prior thrombotic event (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction) – heightened clotting risk.
- History of EPO-induced pure red cell aplasia (PRCA) or anti-EPO antibodies – all ESA products are contraindicated.
- Elevated baseline hematocrit/polycythemia – further red cell increase causes life-threatening hyperviscosity.
- Active or recent malignancy (with curative treatment intent) – ESAs may increase tumor progression and mortality.
- Untreated iron deficiency or other (B12, folate) deficiency – must be corrected first, otherwise treatment is ineffective.
- Competitive sport: WADA bans all forms (class S2) – its use is doping and is sanctioned independently of the medical risks above.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Effect of rhEPO administration on serum levels of sTfR and cycling performance.
Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Haug E, Bahr R
Effects of exercise on the isoelectric patterns of erythropoietin.
Lamon S, Martin L, Robinson N, Saugy M, Ceaurriz J, Lasne F
Mapping of the Pharmacological Effect of Prohibited Substances and Methods to Athletic Physiological Characteristics.
Hayward G, Gaborini L, Robinson N
A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: The Trial-EPO Study.
Haider T, Diaz V, Albert J, Strassburger K, Caicedo A, Reichkendler MH, Lundby C, Gassmann M
Telegram
Have a question about EPO?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.